|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.8780 - 5.3500|
|52 Week Range||2.3100 - 13.9600|
|Beta (5Y Monthly)||-3.48|
|PE Ratio (TTM)||8.33|
|Earnings Date||Apr 15, 2021 - Apr 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.25|
Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test on Thursday to differentiate between COVID-19 and common winter diseases. Novacyt said its "Winterplex" test panel included two gene targets specific to COVID-19, as well as gene targets for influenza A&B and respiratory syncytial virus (RSV). "We believe Winterplex™ is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases," Novacyt CEO Graham Mullis said.
Clinical diagnostics company Novacyt - one of many healthcare companies whose shares have surged during the pandemic - announced on Monday more new products to test for the presence of the coronavirus. Novacyt said it was developing a respiratory testing panel to diagnose and distinguish between the 'A' and 'B' types of influenza, the respiratory syncytial virus (RSV) and COVID-19, with the launch of this product expected in September in time for the 2020/21 flu season in the northern hemisphere. "The immediate pipeline of new products is expected to drive incremental revenue for the company in the near-term, but Novacyt's strengthened financial position also means we are able to redefine our R&D pipeline for the next three years, which we expect to drive significant and continued growth opportunities in the longer-term," said Novacyt CEO Graham Mullis.